| Literature DB >> 34374298 |
Amy Lavelle1, Janine Micheli1.
Abstract
Tweetable abstract One year later, the impact of the COVID-19 pandemic on business practices, supply chains, timelines and analytical needs for COVID-19 clinical trials have been felt across the bioanalytical community, as therapeutics may now require SARS-CoV-2 antigen and serological testing.Entities:
Keywords: COVID-19; NAAT; SARS-CoV-2 antigen; bioanalysis; clinical trials; serology
Year: 2021 PMID： 34374298 DOI： 10.4155/bio-2021-0103
Source DB: PubMed Journal: Bioanalysis ISSN： 1757-6180 Impact factor: 2.681